|
|||||
|
|
A phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitis |
|
| Authors: | Johnny Peppers Amy S. Paller Tomoko Maeda-Chubachi Sterling Wu Kevin Robbins Kelly Gallagher John E. Kraus |
| Affiliation: | 1. PRA Health Sciences, Raleigh, North Carolina;2. Feinberg School of Medicine, Northwestern University, Chicago, Illinois;3. Novan Inc, Morrisville, North Carolina;4. GlaxoSmithKline, Collegeville, Pennsylvania;5. ICON plc, Research Triangle Park, North Carolina |
| Abstract: | |
| Keywords: | atopic dermatitis GSK2894512 tapinarof therapeutic aryl hydrocarbon receptor modulating agent AE adverse event AhR aryl hydrocarbon receptor BSA body surface area CI confidence interval EASI Eczema Area and Severity Index EASI75 75% or greater improvement in Eczema Area and Severity Index score IGA Investigator's Global Assessment NRI nonresponder imputation NRS numeric rating scale TEAE treatment-emergent adverse event |
| 本文献已被 ScienceDirect 等数据库收录！ | |